Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with severe COVID-19 (5 point on NIH 8-point ordinal scale).~* Male or female adult ≥18 years of age at time of enrollment;~* Biological samples (not limited to any specific type) collected within 72 hours before randomization is laboratory-confirmed as SARS-CoV-2 infection (PCR or antigen-based diagnostic tests);~* ≤ 10 days since symptoms of COVID-19 onset.~Exclusion Criteria:~* Patients who need non-invasive ventilation or high flow oxygen (i.e., 6 point on the 8-point ordinal scale);~* Patients with critical COVID-19;~* Patients with Severe COVID-19 who received convalescent plasma or COVID-19 vaccine, or anti-SARS-CoV-2 spike (S) protein targeted therapy;~* Alanine-amino transferase (ALT) or aspartate transaminase (AST) is 5 times higher than the upper limit of the normal value;~* Estimated glomerular filtration rate (eGFR) \<30 mL/min or on dialysis {eGFR calculated by Cockcroft-Gault formula (Cockcroft DW, 1976), Male: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 1/ \[SCr (mg/dL) × 72\]; Female: CrCL (mL/min) = \[(140 - age) × weight (kg)\] × 0.85/ \[SCr (mg/dL) × 72\]}.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SCTA01 Low Dose+BSC (Type: EXPERIMENTAL): SCTA01in a lower dose+best supportive care
- SCTA01 High Dose+BSC (Type: EXPERIMENTAL): SCTA01in a higher dose+best supportive care
- Placebo+BSC (Type: ACTIVE_COMPARATOR): SCTA01 excipients+best supportive care

Based on this trial design, predict the completion outcome and termination type (if applicable).